Reviewed: 2026-04-16 · By the Peptide Protocol editorial team
A ranking of peptides used for cognitive performance, memory, and neuroprotection. The evidence here is thinner than for fat loss or recovery — only one compound has controlled human trials in neurological indications. We've flagged the evidence gap at every step.
Evidence warning: "Nootropic peptide" is mostly a marketing category. The cleanest clinical data is for post-stroke and dementia indications, not healthy-user cognitive enhancement. If you're considering these for memory concerns, get a neurological workup first.
The short version
Cerebrolysin — porcine brain-derived peptide mixture; approved in Russia and Eastern Europe; has stroke and dementia trial data.
Dihexa — HGF/c-Met agonist; preclinical cognitive data is strong, human trials are absent.
NAD+ — cognitive claims are indirect, via mitochondrial and sirtuin mechanisms.
MOTS-c — mitochondrial-derived peptide; early metabolic data doesn't yet extend to cognition.
Thymosin Alpha-1 — primarily immunomodulatory; cognitive fatigue from chronic inflammation is its indirect route.
Cognitive effectModest cognitive improvement in post-stroke, vascular dementia, and Alzheimer's trials
FDANot approved in US/UK/AU/CA; approved in Russia, CIS, parts of EU and Asia
CadenceIM or IV courses of 10–30 days, often cycled
Cerebrolysin is the only compound on this list with real randomized-trial data in clinical cognitive indications. Several meta-analyses of post-stroke and Alzheimer's populations show a modest but reproducible benefit on cognitive scales. The limitations: evidence is strongest in disease populations (not healthy users), quality varies across trials, and the product isn't available through conventional prescription routes in most Western markets.
Strengths
Multiple RCTs and meta-analyses in cognitive populations
Data is strongest in stroke/dementia, not healthy users
Requires IM or IV administration in courses
Not legally imported for personal use in US/UK/AU/CA
Porcine source — allergy and ethical considerations
2.
Dihexa
ClassAngiotensin IV analog; HGF/c-Met activator
Cognitive effectDendritic spinogenesis and memory improvement in rodent models
FDANot approved; no completed human trials
CadenceOral or sublingual; daily
Dihexa is the most-cited "nootropic peptide" in longevity and biohacking communities, based on preclinical rodent data showing BDNF-independent dendritic spinogenesis and memory improvements. Those effects are striking in animals — and entirely unreplicated in humans. The mitogenic mechanism (HGF/c-Met activation) raises theoretical tumor-promotion concerns that no human safety study has addressed.
Strengths
Strong preclinical memory and neuroplasticity data
Orally bioavailable — no injection
Mechanism is well-characterized
Trade-offs
Zero human efficacy or safety data
HGF pathway activation is mitogenic — tumor concerns
Research-chem supply; identity and purity variable
Enthusiasm online exceeds the evidence
3.
NAD+
ClassNicotinamide adenine dinucleotide (coenzyme, not strictly a peptide)
Cognitive effectIndirect via mitochondrial function and sirtuin activation
FDANot approved; NR and NMN precursors sold as supplements
CadenceIV infusion, subcutaneous, or oral (as NR/NMN precursors)
NAD+ is included because it's almost universally asked about in cognition and longevity contexts — not because it's a peptide (it isn't). Direct NAD+ infusion has been marketed aggressively for "cognitive clarity," but the human data supporting a cognitive endpoint is weak. The upstream precursors (NR, NMN) have stronger pharmacokinetic data for raising NAD+ tissue levels, but cognitive outcome data for healthy users remains thin.
Strengths
Legitimate metabolic biology underpins the rationale
Oral precursors (NR, NMN) have good safety data
Raises NAD+ in some tissues at pharmacologic doses
Trade-offs
Cognitive-endpoint trials in healthy users are underpowered or absent
IV infusion protocols are expensive and unvalidated
Not a peptide — included because of reader interest
4.
MOTS-c
ClassMitochondrial-derived 16-amino-acid peptide
Cognitive effectIndirect — metabolic and exercise-mimetic effects; cognitive extrapolation is speculative
FDANot approved; in early clinical development
CadenceSubcutaneous; varies widely
MOTS-c is an interesting research peptide with emerging metabolic data — AMPK activation, improved glucose handling, and possible exercise-mimetic effects in mice. Extending that to cognition is speculative: the argument is that metabolic health supports brain health, which is true in general but doesn't mean MOTS-c specifically improves cognition. No direct cognitive trial data exists.
Strengths
Legitimate preclinical metabolic-biology story
Mitochondrial dysfunction is implicated in cognitive aging
Entering early clinical development
Trade-offs
No cognitive-endpoint trials
Mechanism-to-outcome chain is long and speculative
Research-chem quality varies
5.
Thymosin Alpha-1
Class28-amino-acid immunomodulatory peptide
Cognitive effectIndirect — fatigue and brain fog in chronic inflammation contexts may improve
FDANot approved in US; approved in several other markets (Zadaxin) for immune indications
CadenceSubcutaneous, usually 2× weekly
Thymosin Alpha-1 is included as a fifth-place entry because people ask about it for "brain fog" and post-viral cognitive complaints. Its real mechanism is T-cell modulation. If your cognitive complaint is secondary to chronic inflammation, viral reactivation, or an immune dysregulation state, improving that upstream context can indirectly help cognition — but that's not a direct cognitive effect. Don't use it as a nootropic.
Strengths
Real clinical data for immune indications
Favorable safety profile
Useful where cognitive symptoms are secondary to inflammation
Trade-offs
Not a direct cognitive enhancer
No controlled trials for cognition or brain-fog endpoints
Requires ongoing dosing
What this list leaves out
Semax / Selank — Russian nasal peptides with legitimate Eastern-European clinical use for anxiety and cognition. Excluded because our glossary doesn't cover them yet and the Western evidence base is limited.
P21 / FGL — smaller peptides from neurotrophic factor research. Preclinical data only; not in broad use.
BPC-157 — animal neuroprotection data exists but the cognitive translation is not established; better classified as a recovery peptide.
Racetams, noopept, modafinil — small-molecule nootropics, not peptides. Out of scope for this list.
Before you decide anything
New or persistent cognitive complaints — memory loss, word-finding difficulty, confusion — deserve a neurological workup, not a peptide trial. Many causes (B12 deficiency, thyroid dysfunction, sleep apnea, depression, medication side effects) are correctable without any peptide. For healthy-user "cognitive enhancement," the evidence here is weak and the research-chem supply chain is unreliable. See our medical review process for how we evaluate this content.
Track your protocol on iPhone
Peptide Protocol logs every dose, tracks side effects, and lets you record subjective cognitive notes alongside your schedule.
Educational use only. Nothing on this page constitutes medical advice or a recommendation to use any specific peptide. New or worsening cognitive symptoms should be evaluated by a licensed clinician before any self-directed intervention.
